Published 16th May 2016

TopiVert completes preclinical development of TOP1630

Portfolio company TopiVert, a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, has completed the preclinical development of TOP1630 for the treatment of dry eye disease. Preparations are being made for a Phase I/II study in the US to commence in early 2017.

TOP1630 is a topical anti-inflammatory NSKI being developed for the treatment of dry eye disease, one of the most common ophthalmic diseases worldwide. In moderate to severe cases, sufferers commonly experience debilitating symptoms, including burning, irritation and blurred vision, which can have a considerable impact on quality of life.

Click here to learn more about TOP1630